Vadastuximab talirine

N/A

Report date: 2024/02/05 14:09:12

Base Information

Drug NameVadastuximab talirine

Drug Alias NameAnti-CD33A targeted ADCSGN-CD33A33-A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker > VA linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > PBD dimer SGD-1882 payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionMyeloid cell surface antigen CD33 inhibitorsDNA cross linking agents

TargetsMyeloid cell surface antigen CD33DNA

Therapy Area/IndicationsMyelodysplastic SyndromesLeukemia, Promyelocytic, AcuteLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCzechiaBelgiumUnited States +[16]

CombinationsNo

Global Highest StatusDiscontinued (Phase 3 Clinical)

Highest Status in ChinaN/A

Originator CompaniesSeagen Inc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesSeagen Inc

Active IndicationsN/A

Inactive IndicationsMyelodysplastic SyndromesLeukemia, Promyelocytic, AcuteLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A